Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

84.91
-3.6800-4.15%
Post-market: 85.240.3300+0.39%19:54 EDT
Volume:1.28M
Turnover:109.22M
Market Cap:11.96B
PE:-37.18
High:88.25
Open:87.99
Low:84.20
Close:88.59
52wk High:95.49
52wk Low:21.61
Shares:140.86M
Float Shares:122.00M
Volume Ratio:1.31
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:25.69
PE(LYR):-6,963.83

Loading ...

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Q3 EPS USD -1.36

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Q3 Operating Income USD -170.093 Million

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals - to Use Voucher for Plozasiran Snda in Severe Hypertriglyceridemia Before End of 2026

THOMSON REUTERS
·
Aug 05

Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher

THOMSON REUTERS
·
Aug 05

Arrowhead Pharma Grants 112,794 Inducement RSUs to 95 New Hires

Reuters
·
Aug 04

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 04

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone

Simply Wall St.
·
Aug 03

B. Riley Adjusts Arrowhead Pharmaceuticals Price Target to $123 From $101, Maintains Buy Rating

MT Newswires Live
·
Jul 30

Arrowhead Pharmaceuticals : B. Riley Raises Target Price to $123 from $101

THOMSON REUTERS
·
Jul 30

U.S. Research ROUNDUP-Equinix, Meta, S&P Global

Reuters
·
Jul 30

RBC Raises Price Target on Arrowhead Pharmaceuticals to $100 From $87, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jul 29

Arrowhead Pharmaceuticals : RBC Raises Target Price to $100 from $87

THOMSON REUTERS
·
Jul 29

U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal

Reuters
·
Jul 29

Earning Preview: Arrowhead Pharmaceuticals Q3 revenue is expected to increase by 129%, and institutional views are bullish

Earnings Agent
·
Jul 29

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 Yosemite Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

THOMSON REUTERS
·
Jul 27

Arrowhead Pharmaceuticals - Yosemite Phase 3 Study Completion Anticipated in Mid-2027

THOMSON REUTERS
·
Jul 27

Arrowhead Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 27

Arrowhead price target raised to $126 from $110 at Piper Sandler

TIPRANKS
·
Jul 23

Arrowhead Pharmaceuticals (ARWR) Is Up 23.5% After Strong Plozasiran Phase 3 Data in Severe Hypertriglyceridemia

Simply Wall St.
·
Jul 23